FilingReader Intelligence
SinoMab's SM17 shows positive results in atopic dermatitis trial
April 7, 2025 at 05:04 PM UTC•By FilingReader AI
SinoMab BioScience Limited (HKEX:3681) has announced positive topline results from its Phase 1b clinical trial of SM17 for treating moderate-to-severe atopic dermatitis (AD) in China. The trial demonstrated promising efficacy, particularly in reducing pruritus (itching).
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:3681•Hong Kong Exchange
News Alerts
Get instant email alerts when SinoMab BioScience publishes news
Free account required • Unsubscribe anytime